Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death.
作者信息
Friedrich Jan O, Adhikari Neill K J, Meade Maureen O
出版信息
Crit Care. 2006;10(6):427. doi: 10.1186/cc5117.
Abstract
摘要
相似文献
1
Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death.严重脓毒症且死亡风险高的患者使用活化蛋白C。
Crit Care. 2006;10(6):427. doi: 10.1186/cc5117.
2
Drotrecogin alfa (activated) in severe sepsis.重组人活化蛋白C用于严重脓毒症
N Engl J Med. 2006 Jan 5;354(1):94-6; author reply 94-6. doi: 10.1056/NEJMc052759.
3
Drotrecogin alfa (activated) in severe sepsis.
N Engl J Med. 2006 Jan 5;354(1):94-6; author reply 94-6.
4
Drotrecogin alfa (activated) administration: too many subgroups.重组人活化蛋白C的给药：亚组过多。
Crit Care Med. 2003 Oct;31(10):2564; author reply 2564-5. doi: 10.1097/01.CCM.0000089929.73924.4C.
5
Drotrecogin alfa (activated) in severe sepsis.
N Engl J Med. 2006 Jan 5;354(1):94-6; author reply 94-6.
6
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.重组人活化蛋白C在严重脓毒症患者重要临床亚组中的应用。
Crit Care Med. 2003 Jan;31(1):12-9. doi: 10.1097/00003246-200301000-00002.
7
Criteria for use of drotrecogin alfa.重组人活化蛋白C的使用标准。
Am J Health Syst Pharm. 2004 Jan 15;61(2):203-4; author reply 204-5. doi: 10.1093/ajhp/61.2.203.
8
Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.重组活化蛋白C：从临床试验到临床实践的推广
Eur J Anaesthesiol. 2008 Mar;25(3):211-6. doi: 10.1017/S0265021507002992. Epub 2007 Nov 22.
9
Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death.活化蛋白C：目前的证据支持对有高死亡风险的严重脓毒症患者进行治疗。
Crit Care. 2006;10(5):424. doi: 10.1186/cc5062.
10
Use of drotrecogin alfa (activated) in older patients with severe sepsis.
Pharmacotherapy. 2006 Apr;26(4):533-8. doi: 10.1592/phco.26.4.533.
引用本文的文献
1
Activated protein C in sepsis: the promise of nonanticoagulant activated protein C.脓毒症中的活化蛋白C：非抗凝活化蛋白C的前景
Curr Opin Hematol. 2008 Sep;15(5):487-93. doi: 10.1097/MOH.0b013e32830abdf4.
本文引用的文献
1
Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death.活化蛋白C：目前的证据支持对有高死亡风险的严重脓毒症患者进行治疗。
Crit Care. 2006;10(5):424. doi: 10.1186/cc5062.
2
Drotrecogin alfa (activated): down and not out, but not really in either.重组人活化蛋白C：虽未一蹶不振，但也未真正站稳脚跟。
Crit Care. 2006;10(5):420. doi: 10.1186/cc5022.
3
Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?活化蛋白C：目前的证据是否支持对任何严重脓毒症患者进行治疗？
Crit Care. 2006;10(3):145. doi: 10.1186/cc4947. Epub 2006 Jun 2.
4
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.重组人活化蛋白C用于严重脓毒症且死亡风险较低的成人患者。
N Engl J Med. 2005 Sep 29;353(13):1332-41. doi: 10.1056/NEJMoa050935.
5
Measuring inconsistency in meta-analyses.评估荟萃分析中的异质性
BMJ. 2003 Sep 6;327(7414):557-60. doi: 10.1136/bmj.327.7414.557.
6
Efficacy and safety of recombinant human activated protein C for severe sepsis.重组人活化蛋白C治疗严重脓毒症的疗效与安全性
N Engl J Med. 2001 Mar 8;344(10):699-709. doi: 10.1056/NEJM200103083441001.
Zotero 插件